Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions

12 de noviembre de 2026 actualizado por: Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Diagnostic Performance and Safety of Ragweed Pollen and Dog Dander Skin Prick Test Solutions in Chinese Participants Undergoing Allergy Testing

This multicenter, open-label, Phase III interventional study will evaluate the diagnostic performance and safety of ragweed pollen and dog dander skin prick test (SPT) solutions in adults in China with current or previous allergic diseases. Participants will undergo serum allergen-specific immunoglobulin E (sIgE) testing using the Thermo Fisher Scientific ImmunoCAP system. Each enrolled participant will receive one skin prick with ragweed pollen solution (3,500 DU/mL), dog dander solution (19,500 DU/mL), dog dander solution (39,000 DU/mL), and positive and negative controls. Wheal responses will be assessed 15-20 minutes after skin pricking. Diagnostic sensitivity and specificity will be determined separately for each test solution against the corresponding serum sIgE classification (cutoff ≥0.70 kUA/L). Safety will be assessed through adverse events, symptoms, vital signs, physical examinations, and laboratory tests.

Descripción general del estudio

Estado

Aún no reclutando

Condiciones

Intervención / Tratamiento

Tipo de estudio

Intervencionista

Inscripción (Estimado)

650

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • Beijing, Porcelana, 100730
        • Beijing Tongren Hospital, Capital Medical University
        • Contacto:
    • Hubei
      • Wuhan, Hubei, Porcelana, 430030
        • Tongji Hospital, Tongji Medical College of Hust
        • Contacto:
          • Zhu Rongfei
          • Número de teléfono: +862783662912
          • Correo electrónico: Zrf13092@163.com
    • Shanxi
      • Taiyuan, Shanxi, Porcelana, 030032
        • Shanxi Bethune Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 60 años (Adulto)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  1. Male or female participants aged 18-60 years, inclusive.
  2. Participants with a current or previous history of allergic diseases, such as allergic rhinitis, allergic conjunctivitis, or allergic asthma.
  3. Participants who are able to understand the study and voluntarily provide written informed consent.

Exclusion Criteria:

  1. History of needle-related syncope or vasovagal reactions to the sight of blood.
  2. Pregnant or breastfeeding women.
  3. History of malignant tumors.
  4. Currently receiving beta-blockers or angiotensin-converting enzyme inhibitors and unable to discontinue treatment during the study.
  5. Currently experiencing a severe allergic reaction or having a history of severe allergic reactions, including generalized urticaria, severe or more serious acute asthma exacerbations, or anaphylactic shock.
  6. Use of topical corticosteroids or topical calcineurin inhibitors at the intended skin prick site within 7 days before SPT.
  7. Systemic use of antihistamines or antihistamine-containing combination medications before SPT, with a discontinuation period not exceeding five elimination half-lives of the antihistamine.
  8. Use of short-acting systemic corticosteroids within 2 days, intermediate-acting systemic corticosteroids within 5 days, or long-acting systemic corticosteroids within 12 days before SPT.
  9. Systemic use of immunosuppressants within 14 days before SPT.
  10. Use of phenothiazine antipsychotics within 10 days or imipramine-class antidepressants within 21 days before SPT.
  11. Treatment with dupilumab or similar agents within 3 months before SPT.
  12. Treatment with omalizumab or similar agents within 5 months before SPT.
  13. Photochemotherapy on the volar surfaces of both forearms within 30 days before SPT.
  14. Skin infection, dermatitis, trauma, scarring, pigmentation, or other pathological changes at the intended volar forearm test site that, in the investigator's judgment, may interfere with SPT interpretation.
  15. Positive skin scratch test for dermographism during screening.
  16. Participation in another drug clinical trial with administration of an investigational product within 1 month before screening, or less than five elimination half-lives since the last administration of that investigational product, whichever period is longer.
  17. Any other condition that, in the investigator's judgment, makes the participant unsuitable for the study.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Diagnóstico
  • Asignación: N / A
  • Modelo Intervencionista: Asignación de un solo grupo
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Skin Prick Test Group

All enrolled participants receive ragweed pollen SPT solution (3,500 DU/mL), dog dander SPT solution (19,500 DU/mL), dog dander SPT solution (39,000 DU/mL), and positive and negative control solutions during the same test session.

One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

One drop applied to the volar forearm, followed by a single skin prick; wheal assessed 15-20 minutes later.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Sensitivity: Ragweed Pollen (3,500 DU/mL)
Periodo de tiempo: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a positive SPT result among participants with serum ragweed sIgE ≥0.70 kUA/L by ImmunoCAP (w1). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Specificity: Ragweed Pollen (3,500 DU/mL)
Periodo de tiempo: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a negative SPT result among participants with serum ragweed sIgE <0.70 kUA/L by ImmunoCAP (w1). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Sensitivity: Dog Dander (19,500 DU/mL)
Periodo de tiempo: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Specificity: Dog Dander (19,500 DU/mL)
Periodo de tiempo: 15-20 minutes after skin prick testing (Day 1).

Measure Description: Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Sensitivity: Dog Dander (39,000 DU/mL)
Periodo de tiempo: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a positive SPT result among participants with serum dog dander sIgE ≥0.70 kUA/L by ImmunoCAP (e5). An SPT is positive when maximum wheal diameter is ≥3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).
Specificity: Dog Dander (39,000 DU/mL)
Periodo de tiempo: 15-20 minutes after skin prick testing (Day 1).

Percentage of participants with a negative SPT result among participants with serum dog dander sIgE <0.70 kUA/L by ImmunoCAP (e5). An SPT is negative when maximum wheal diameter is <3 mm, provided control validity criteria are met.

15-20 minutes after skin prick testing (Day 1).

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Adverse Events
Periodo de tiempo: From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.

Number and percentage of participants experiencing adverse events, adverse drug reactions, serious adverse events, serious adverse drug reactions, and adverse events leading to withdrawal, by test solution as applicable.

From first skin prick administration (Day 1) through the final study visit (approximately 24 hours +4 hours after testing), with follow-up of unresolved events as required by protocol.
Changes in Vital Signs from Baseline
Periodo de tiempo: At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.

Changes in vital signs from baseline will be assessed, including body temperature (°C), systolic and diastolic blood pressure (mmHg), and pulse rate (beats/min). Descriptive statistics, including mean, median, standard deviation, quartiles, minimum, and maximum, will be presented.Changes in vital signs will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening, within 2 hours before SPT, 1 hour ±10 minutes after SPT, and 24 hours ±4 hours after SPT.
Changes in Physical Examination Findings from Baseline
Periodo de tiempo: At screening and on Day 2 of the study or at early termination.

Changes in physical examination findings from baseline will be assessed, including skin and mucosa, lymph nodes, head and neck, chest, abdomen, and spine and extremities. Changes in examination findings will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening and on Day 2 of the study or at early termination.
Changes in Hematology Parameters from Baseline
Periodo de tiempo: At screening and on Day 2 of the study or at early termination.

Changes in hematology parameters from baseline will be assessed, including white blood cell count; absolute and percentage counts of neutrophils, lymphocytes, monocytes, eosinophils, and basophils; red blood cell count; hemoglobin; and platelet count. Units of measurement will follow the laboratory reports. Quantitative results will be summarized using the mean, median, standard deviation, quartiles, minimum, and maximum. Changes in clinical assessment categories will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening and on Day 2 of the study or at early termination.
Changes in Urinalysis Parameters from Baseline
Periodo de tiempo: At screening and on Day 2 of the study or at early termination.

Changes in urinalysis parameters from baseline will be assessed, including urine bilirubin, glucose, ketones, protein, occult blood, and leukocytes or leukocyte esterase. Results will be summarized according to the categories reported by the laboratory. Changes in results will be summarized using cross-tabulations. Clinically significant abnormalities will be listed.

At screening and on Day 2 of the study or at early termination.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Estimado)

11 de noviembre de 2026

Finalización primaria (Estimado)

1 de junio de 2027

Finalización del estudio (Estimado)

1 de octubre de 2027

Fechas de registro del estudio

Enviado por primera vez

5 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Publicado por primera vez (Actual)

18 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

18 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

12 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • WOLWO-D1-0III32-1

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .